| Literature DB >> 27630127 |
.
Abstract
A phase III trial suggests that the combination of daratumumab, bortezomib, and dexamethasone is more powerful in patients with relapsed or relapsed and refractory melanoma than bortezomib plus dexamethasone. Patients who received all three drugs had a higher overall response rate and improved 12-month progression-free survival. ©2016 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27630127 DOI： 10.1158/2159-8290.CD-NB2016-115
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397